How is a treatment plan made?
After a leukemia diagnosis, the most common question is: “What happens now?” A treatment plan is not chosen at random. It is based on the exact type of leukemia, its genetic features, the person’s age, general health and wishes. This topic explains in plain language how a plan is built, what phases it usually has and what your role is in the process.
01Short answer
02Simple explanation
Leukemia is not one disease but a group of different diseases. That is why there is no single plan for everyone. Treatment for acute myeloid leukemia, acute lymphoblastic leukemia and the chronic leukemias differs a great deal.
To build a plan, doctors first gather complete information: blood count, bone marrow tests, flow cytometry, cytogenetics and molecular tests. Some genetic results arrive a few days later and fine-tune the plan.
In acute leukemia, treatment is usually given in phases. The aim of the first phase, induction, is to reach remission, meaning the leukemia cells fall so low that they can no longer be seen in the tests. Later phases aim to destroy the cells that remain.
In some chronic leukemias, such as early CLL without symptoms, treatment may not be needed straight away. The doctor may suggest active monitoring: regular check-ups, with treatment started when it is really needed.
You are part of this process. Asking questions, asking for explanations, taking time to think (except in emergencies) and getting a second opinion are all your rights.
03Scientific explanation
What shapes the plan: according to NCI, leukemia treatment depends on its type and subtype, whether it has spread to places such as the central nervous system, its genetic changes, whether it has been treated before, and the person’s age and general condition. The 2022 ELN recommendations define genetic risk groups in AML (favorable, intermediate, adverse), and these groups guide later decisions, such as whether a transplant is advised.
Phases in acute leukemia: according to NCI, AML treatment usually has two phases, remission induction and post-remission (consolidation) therapy. In ALL, maintenance therapy and treatment aimed at preventing spread to the central nervous system are added; in children, ALL treatment usually lasts 2–3 years in total. Acute promyelocytic leukemia (APL) is an emergency: treatment may start as soon as it is suspected, without waiting for genetic confirmation.
Chronic leukemias: according to NCI, the main treatment for chronic-phase CML is tyrosine kinase inhibitors, usually taken long term. In CLL, the iwCLL criteria define when treatment should start (for example, worsening blood counts, symptoms or rapid growth); when these signs are absent, monitoring is the standard approach.
Consent and choices: according to the American Cancer Society, informed consent is given after the purpose, benefits, risks and alternatives of treatment have been understood. ASCO guidance says fertility preservation should be discussed as early as possible, before treatment that may affect the ability to have children. Clinical trials may also be an option; NCI describes them as studies that test the safety and effectiveness of new treatments.
04What happens in the body?
Who is on the team?
The plan is usually led by a hematologist (a doctor for blood diseases). The team may include specially trained nurses, a clinical pharmacist, laboratory specialists, an infectious disease doctor, a psychologist, a social worker and a dietitian. In complex cases the results are discussed together at a multidisciplinary team meeting.
What is the goal of treatment?
The goal may be to get rid of the leukemia completely (cure), to keep it under control for a long time, or to ease symptoms. It is normal to ask your doctor directly about the goal. Palliative (supportive) care focuses on quality of life and can be given at any stage alongside the main treatment.
How is the result checked?
At set points in treatment, blood counts and often a bone marrow test are repeated. Doctors look at whether there is remission and whether residual disease (MRD) remains. These results decide the next step, for example continuing treatment, changing it or moving to a transplant.
Why might the plan change?
Some genetic results arrive after treatment has started and may lead to an extra medicine being added. Side effects, infections or the response to treatment can also change the plan. This is not a mistake; it means the plan is being adapted to your situation.
Where does treatment take place?
The intensive phases of acute leukemia treatment, especially induction, are often given in hospital and may take several weeks, because blood counts fall very low during this time and the risk of infection is high. Some phases, and treatment for chronic leukemias, are given as an outpatient, in a day unit or at home as tablets. Ask your team where and how you will be treated, and which warning signs at home mean you should call straight away.
05How is a plan built?
Four steps from diagnosis to treatment.
06An overview of treatment plans (simplified)
| Leukemia type | Typical plan structure | Note |
|---|---|---|
| AML | Induction, then consolidation; a transplant in some cases | The genetic risk group guides decisions |
| APL | Treatment that makes the cells mature is started urgently | An emergency because of bleeding risk |
| ALL | Induction, consolidation, maintenance, brain-directed prevention | Total length often 2–3 years |
| CML | Long-term targeted medicine (tablets) | Regular molecular monitoring |
| CLL | Monitoring first, or treatment when there is a clear reason | Criteria for starting are well defined |
* This table shows only the general picture; every person’s plan is individual. Your treatment is decided only by your hematology team.
07Key terms
- Treatment plan
- A road map: which treatment, in what order and for how long.
- Induction
- The first intensive phase of acute leukemia treatment, aiming for remission.
- Consolidation
- The phase after remission that aims to destroy remaining leukemia cells.
- Maintenance
- Longer, gentler treatment to prevent relapse (especially in ALL).
- Remission
- When signs of leukemia in the tests fall below a set threshold.
- MRD
- Measurable residual disease: a few leukemia cells not visible under an ordinary microscope.
- Risk group
- A classification of leukemia by its expected response to treatment.
- Active monitoring
- Watching without treatment, with regular checks, while there are no symptoms.
- Informed consent
- Agreement given after understanding the benefits, risks and alternatives.
- Clinical trial
- A study testing the safety and effectiveness of a new treatment in volunteers.
08Key points
- The plan is based on the leukemia type and its genetics.
- Age, general health and your wishes are also considered.
- Acute leukemia is treated in phases.
- Some chronic leukemias may be monitored at first.
- The response is checked with blood and bone marrow tests.
- The plan may change with new results.
- Discuss fertility before treatment starts.
- Asking questions and getting a second opinion are your rights.
09Frequently asked questions
How soon does treatment need to start?
It depends on the type of leukemia. In acute leukemias, especially APL, treatment often starts urgently. In some chronic leukemias there may be no need to hurry. Your hematologist decides the timing.
Can treatment start before the genetic results are back?
Sometimes, yes. In acute leukemia, treatment may begin before some genetic results are available, and the plan is then refined. This is common and safe practice.
Will my doctor be offended if I want a second opinion?
Usually not. Second opinions are common and accepted. The only important point in acute leukemia is that it should not delay treatment; talk about this openly with your team.
Can I refuse treatment?
Yes, that is your right. But before deciding, it is important to discuss the possible consequences of refusing, and the alternatives, in detail with your doctor.
Is taking part in a clinical trial dangerous?
Trials are run under strict rules and oversight. Each trial has its own benefits and risks. Taking part is voluntary and you can leave at any time. Ask your hematologist whether a suitable trial exists.
What questions should I ask my doctor?
For example: “What exact type and risk group is my leukemia?”, “What is the goal of treatment?”, “How long will it last?”, “What side effects are expected?”, “When should I call straight away?” Writing your questions down beforehand helps.
10Questions for your doctor
Take these questions to your appointment. The ones you save are collected on the “My questions” page and stay on this device only.
How was my treatment plan made, and which factors were considered?
Are there other treatment options for me?
Could I take part in a clinical trial?
Can I have a written copy of my treatment plan?
12Sources
- National Cancer Institute (NCI). Questions to Ask about Cancer Treatment
- National Cancer Institute (NCI). Types of Cancer Treatment
- National Cancer Institute (NCI). What Are Clinical Trials?
- National Cancer Institute (NCI). Acute Myeloid Leukemia Treatment (PDQ®) — Patient Version
- National Cancer Institute (NCI). Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®) — Patient Version
- National Cancer Institute (NCI). Chronic Myeloid Leukemia Treatment (PDQ®) — Patient Version
- National Cancer Institute (NCI). Chronic Lymphocytic Leukemia Treatment (PDQ®) — Patient Version
- American Cancer Society. Making Treatment Decisions
- American Cancer Society. Informed Consent
- American Cancer Society. Second Opinions for Cancer Treatment
- American Cancer Society. Typical Treatment of Acute Myeloid Leukemia (Except APL)
- American Cancer Society. Typical Treatment of Acute Lymphocytic Leukemia
- Blood (American Society of Hematology), 2022. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
- Journal of Clinical Oncology, 2018. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update